MSN Laboratories Private Limited
Records under this name other than the patents MSN Laboratories Private Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Back to MSN Laboratories Private Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,279,696 | Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one Lapsed on the fee record Ended Mar 22, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 22, 2026 | USPTO record |
| US 10,913,762 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof Lapsed on the fee record Ended Feb 9, 2025 · USPTO record | Lapsed on the fee record | Ended Feb 9, 2025 | USPTO record |
| US 10,633,372 | Process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5-(4 fluorophenyl)-2-thienyl]-4-methylphenyl]-D-glucitol and its polymorphs thereof Lapsed on the fee record Ended Apr 28, 2024 · USPTO record | Lapsed on the fee record | Ended Apr 28, 2024 | USPTO record |
| US 10,633,390 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form Lapsed on the fee record Ended Apr 28, 2024 · USPTO record | Lapsed on the fee record | Ended Apr 28, 2024 | USPTO record |
| US 10,562,931 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone Lapsed on the fee record Ended Feb 18, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 18, 2024 | USPTO record |
| US 10,550,107 | Process for the preparation of N-[4-[(3-chloro-4-fluoro phenyl) amino]-7-[[(3s-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethyl amino)-(2E)-2-butenamide (2Z)-2-butenedioate (1:2) and its polymorphs thereof Lapsed on the fee record Ended Feb 4, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 4, 2024 | USPTO record |
| US 10,544,189 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide Lapsed on the fee record Ended Jan 28, 2024 · USPTO record | Lapsed on the fee record | Ended Jan 28, 2024 | USPTO record |
| US 9,102,664 | Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof Lapsed on the fee record Ended Aug 11, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 11, 2023 | USPTO record |
| US 10,301,302 | Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof Lapsed on the fee record Ended May 28, 2023 · USPTO record | Lapsed on the fee record | Ended May 28, 2023 | USPTO record |
| US 9,006,448 | Process for the preparation of benzimidazole derivatives and its salts Lapsed on the fee record Ended Apr 14, 2023 · USPTO record | Lapsed on the fee record | Ended Apr 14, 2023 | USPTO record |